Simplify Logo
LabCorp

LabCorp

Global life sciences R&D services

Medical Director - Multiple Teams

Full-TimeDeadline 9/30/26
$320k - $340k/yr
Senior, Expert
MD
Remote in USA+1 more

More locations: Durham, NC, USA

Remote

Remote within the United States; travel up to 30% is required.

About the job

Requirements
  • An M.D. or D.O. degree from an accredited medical school.
  • Board certification in Medical Oncology.
  • At least 5 years of post-fellowship clinical experience treating patients with solid tumors.
  • At least 3 years of oncology clinical development, clinical research, clinical trial leadership, or evidence-generation experience within a pharmaceutical, biotechnology, diagnostics, contract research organization, or academic research environment.
  • At least 8 years of experience designing, leading, or supporting prospective and/or retrospective clinical studies, including protocol development, endpoint selection, study conduct, data analysis, interpretation, and publication of results.
  • At least 5 years of experience working in cross-functional environments with operations, biostatistics, regulatory affairs, medical affairs, research and development, commercial, and/or market access teams.
  • At least 20 presentations delivered to scientific congresses, investigators, key opinion leaders, healthcare providers, advisory boards, or medical education forums.
  • Strong understanding of oncology clinical trial methodology, study design, evidence generation, biostatistics, and regulatory requirements.
  • Broad knowledge of solid tumor treatment paradigms, clinical guidelines, biomarkers, and precision oncology approaches.
  • Expertise in clinical trial design, protocol development, biostatistics, epidemiology, and evidence-generation methodologies.
Responsibilities
  • Serve as the clinical development lead for the minimal residual disease portfolio across solid tumors, providing strategic medical leadership for evidence generation, product development, and clinical adoption initiatives.
  • Develop and execute clinical development strategies supporting minimal residual disease and circulating tumor DNA-based technologies across multiple tumor types, disease settings, and clinical applications.
  • Lead the medical design and clinical oversight of evidence-generation programs establishing the clinical validity, clinical utility, and health economic value of minimal residual disease testing.
  • Drive alignment across internal stakeholders involved in clinical studies, evidence generation, and product development activities.
  • Translate emerging clinical data into recommendations informing portfolio strategy, indication expansion, product development, and clinical adoption.
  • Serve as the senior clinical subject matter expert for minimal residual disease technologies and applications across the oncology portfolio.
  • Support investigator-initiated studies, strategic research collaborations, and real-world evidence programs expanding the evidence base for minimal residual disease testing.
  • Provide medical leadership for the minimal residual disease portfolio throughout the product lifecycle, from concept development through commercialization and lifecycle management.
  • Define clinical evidence requirements, intended-use populations, clinical claims, validation strategies, and evidence-generation priorities needed to support product adoption and clinical implementation.
  • Partner with research and development, product, and innovation teams to guide assay development, biomarker strategies, and next-generation technology initiatives.
  • Evaluate competitive technologies, emerging biomarkers, and evolving standards of care to inform portfolio priorities and future investment decisions.
  • Act as the primary medical advisor for minimal residual disease portfolio strategy and indication expansion opportunities.
  • Partner with market access teams to develop and execute evidence-generation strategies supporting payer coverage, reimbursement, and health-system adoption.
  • Provide medical leadership for studies demonstrating clinical utility, effects on physician decision-making, patient outcomes, and economic value.
  • Support interactions with payers, policy stakeholders, and guideline organizations by communicating the clinical rationale and value proposition of minimal residual disease testing.
  • Contribute to strategies supporting inclusion of minimal residual disease testing within clinical practice guidelines, treatment pathways, and value-based care models.
  • Ensure clinical development priorities and evidence-generation plans align with reimbursement, market access, and adoption objectives.
  • Build and maintain strategic relationships with oncology investigators, academic medical centers, cooperative groups, professional societies, and industry partners.
  • Serve as the physician lead for external scientific collaborations, investigator engagement, and evidence-generation partnerships supporting minimal residual disease technologies.
  • Influence the evolution of minimal residual disease clinical applications through engagement with key opinion leaders, scientific experts, and research organizations.
  • Represent Labcorp Oncology as a scientific expert at congresses, advisory boards, investigator meetings, and external scientific forums.
  • Engage key opinion leaders to support clinical development strategy, evidence generation, and long-term portfolio planning.
  • Provide medical leadership and post-launch support for minimal residual disease products, including interpretation of clinical evidence, management of complex clinical questions, and support for appropriate clinical implementation.
  • Serve as a clinical resource for healthcare providers regarding minimal residual disease testing and integration of results into patient management.
  • Provide medical expertise and scientific guidance for educational initiatives supporting minimal residual disease adoption across solid tumors, including tumor boards, webinars, educational programs, and scientific exchange activities.
  • Partner with medical affairs, commercial, and marketing teams to develop scientifically accurate and clinically meaningful educational content.
  • Lead publication planning and support development of manuscripts, abstracts, presentations, congress submissions, and peer-reviewed publications.
  • Maintain scientific rigor and ensure evidence is effectively communicated to clinical, scientific, and payer audiences.
  • Serve as the clinical development leader for the minimal residual disease portfolio, driving strategy and execution through scientific expertise, influence, and cross-functional collaboration rather than direct people management.
  • Align stakeholders around shared clinical development priorities, evidence-generation plans, and portfolio objectives.
  • Provide expert guidance to clinical, scientific, operational, and commercial colleagues supporting minimal residual disease initiatives.
  • Influence organizational decision-making through scientific insight, clinical expertise, and strategic recommendations.
  • Contribute to clinical development processes, best practices, and organizational capabilities supporting Labcorp Oncology's precision oncology portfolio.
  • Mentor colleagues and provide scientific guidance to project teams, medical affairs partners, and other stakeholders.
  • Lead cross-functional discussions regarding clinical development strategy, evidence-generation priorities, portfolio investments, and indication expansion opportunities.
  • Support regulatory submissions and interactions through clinical expertise, scientific rationale, and interpretation of evidence.
  • Partner with commercial and market access teams to align clinical evidence generation with customer, payer, and healthcare system needs.
  • Monitor emerging scientific, clinical, technological, and competitive developments to inform strategic decision-making and future portfolio direction.
Desired Qualifications
  • At least 5 years of experience in molecular diagnostics, liquid biopsy, minimal residual disease, circulating tumor DNA, precision oncology, or biomarker-driven clinical development.
  • At least 5 years of industry experience within diagnostics, biotechnology, pharmaceutical, or life sciences organizations, with responsibility for oncology product development, medical affairs, clinical development, or translational research.
  • At least 3 years of experience serving as a medical lead, clinical development lead, or equivalent leadership role for an oncology assay, biomarker, diagnostic, or therapeutic development program.
  • At least 5 years of experience leading oncology clinical development programs, evidence-generation initiatives, or translational research activities across multiple solid tumor indications.
  • At least 3 studies or evidence-generation programs supporting clinical utility, reimbursement, payer coverage, guideline inclusion, or adoption of oncology diagnostics or precision medicine products.
  • At least 3 years of experience partnering with Market Access teams to develop evidence-generation strategies supporting value demonstration, reimbursement, and commercial adoption.
  • At least 3 years of direct people leadership experience, including management, mentoring, and performance development of physicians, scientists, and/or cross-functional clinical teams.
  • At least 20 peer-reviewed publications, scientific presentations, and participation at major oncology congresses.
  • Participation in at least 2 regulatory submissions, product launches, or major lifecycle management initiatives in oncology, molecular diagnostics, precision medicine, or related therapeutic areas.

About the company

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Get referred to LabCorp

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Investor Day on September 10, 2026 guided 5% to 8% revenue CAGR through 2029.
  • Labcorp launched a hepatitis D reflex test on August 25, 2026, broadening specialty diagnostics.
  • The OHSU MRD bladder cancer study on September 9, 2026 strengthens oncology companion revenue.

What critics are saying

  • The September 4, 2026 website-tracking settlement restricts Meta Pixel and Google Analytics for two years.
  • Labcorp faces post-settlement compliance reporting, senior oversight, and litigation headlines through 2028.
  • A major data or compliance scandal would erode trust with sponsors and hospitals.

What makes LabCorp unique

  • Labcorp spans diagnostics and biopharma labs, supporting 85% of FDA-approved new drugs in 2025.
  • MLM acquisition on September 8, 2026 created wholly owned central labs across four continents.
  • Global Trial Connect upgrades on August 31, 2026 deepen sponsor workflows and visibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Tuition Reimbursement

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Sep 12th, 2026
Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A

Evvy, a female-founded startup unlocking precision women’s healthcare through biomarker discovery, announced today the closing of a $14 million Series A fund...

PR Newswire
Sep 10th, 2026
Labcorp targets 5-8% annual revenue growth through 2029 at investor day

Labcorp hosted its 2026 Investor Day on 10 September, outlining its growth strategy and long-term financial outlook through 2029. The company expects compound annual revenue growth of 5% to 8% and adjusted earnings per share growth of 8.5% to 11.5% through 2029. Chairman and CEO Adam Schechter said Labcorp is positioned at the intersection of diagnostics, biopharma, science and technology. The company reaffirmed its 2026 guidance, projecting enterprise revenue growth of 5.4% to 6.3%. Labcorp's Diagnostics Laboratories division is expected to grow 5.3% to 6.0%, whilst Biopharma Laboratory Services is forecast to grow 5.5% to 6.5%. Chief Financial Officer Julia Wang cited the company's proven delivery record and disciplined value creation framework as underpinning this outlook. The company employs nearly 71,000 people and serves clients in approximately 100 countries.

PR Newswire
Sep 8th, 2026
Labcorp acquires MLM Medical Labs to become only central laboratory provider with wholly owned network across four continents

Labcorp has acquired MLM Medical Labs, a global central and specialty laboratory provider with operations in the United States, Germany and South Africa. Financial terms were not disclosed. The acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa. MLM operates Africa's first fully CAP-accredited central laboratory. The deal expands Labcorp's presence in key clinical research regions and strengthens its biomarker and specialty testing capabilities. It enhances the company's ability to support multinational clinical trials with consistent scientific, operational and regulatory oversight. Labcorp employs nearly 71,000 people serving clients in approximately 100 countries.

BioPharma Watch
Sep 8th, 2026
Labcorp acquires MLM Medical Labs, expanding global central laboratory and biomarker capabilities for clinical trials.

Labcorp acquires MLM Medical Labs, expanding global central laboratory and biomarker capabilities for clinical trials. Key Takeaway: Labcorp has acquired MLM Medical Labs, enhancing its global laboratory services and biomarker capabilities. This acquisition positions Labcorp as the only central laboratory provider with a wholly owned network across four continents. It aims to support complex clinical trials with improved scientific and operational oversight, particularly in emerging markets like Africa. Market sentiment analysis. Positive FACTORS. * Acquisition enhances Labcorp's global laboratory network. * Strengthens biomarker and specialty testing capabilities. * Supports complex multinational clinical trials. * Establishes Labcorp as a leader in central laboratory services. Acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents BURLINGTON, N.C., Sept. 8, 2026 /PRNewswire/ - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed. The acquisition enhances Labcorp's position as a leading independent central laboratory services provider by expanding its presence in key clinical research regions and strengthening its biomarker and specialty testing capabilities. The transaction expands Labcorp's laboratory footprint and establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa. The combination brings together Labcorp's global scale, breadth of scientific capabilities and operational infrastructure with MLM's established laboratory network and science-led service model. "Clinical trial sponsors today need scientific expertise, global reach and operational flexibility to advance increasingly complex development programs," said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "MLM complements Labcorp's existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies. Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide." This integrated global infrastructure enhances Labcorp's ability to support complex multinational clinical trials with consistent scientific, operational and regulatory oversight from a single trusted partner. The acquisition also expands Labcorp's laboratory footprint in critical clinical research markets, including Africa, where MLM operates the continent's first fully CAP-accredited central laboratory. In addition, the acquisition strengthens Labcorp's scientific and regulatory expertise and broadens access to biomarker and specialty testing capabilities that support increasingly complex clinical development programs. This acquisition reflects Labcorp's ongoing commitment to investing in central laboratory services and meeting the evolving needs of clinical trial sponsors worldwide. Evercore served as exclusive financial advisor to Labcorp and Pierson Ferdinand and Hogan Lovells served as Labcorp's legal counsel. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. BiopharmaWatch provide insights and advance science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to the acquisition of MLM Medical Labs and how its capabilities are anticipated to benefit clinical trial sponsors. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS." Frequently asked questions. What is the significance of Labcorp's acquisition of MLM? The acquisition enhances Labcorp's global laboratory network and strengthens its biomarker testing capabilities. How does this acquisition impact clinical trials? It supports complex multinational clinical trials with improved scientific and operational oversight. Where does MLM operate? MLM has operations in the United States, Germany, and South Africa. What regions will Labcorp's network cover after the acquisition? Labcorp will have a wholly owned laboratory network across North America, Europe, Asia, and Africa.

PR Newswire
Sep 5th, 2026
If you conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026, a class action settlement may affect you.

If you conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026, a class action settlement may affect you. Sep 04, 2026, 20:00 ET GREENSBORO, N.C., Sept. 4, 2026 /PRNewswire/ - WHAT IS THIS ABOUT? Plaintiffs allege that Labcorp violated California and Pennsylvania wiretapping laws by facilitating, through third-party tracking technologies, the interception of personally identifiable information and searches that users conducted on Labcorp's website. Labcorp denies these and all other allegations of wrongdoing and liability, and denies all claims asserted against it. Plaintiffs and Labcorp have agreed to a settlement to resolve this lawsuit. The Court has not decided who is right or wrong. WHO IS INCLUDED? The Settlement Classes are defined as follows: * California Settlement Class: All persons in California who conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026. * Pennsylvania Settlement Class: All persons in Pennsylvania who conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026. "Search Queries" means search terms and/or search queries, including but not limited to, entry of any search term(s) into a search bar or search menu on the Labcorp website, www.labcorp.com and its subpages, as well as making any selection(s) from any drop-down menu on the website. WHAT DOES THE SETTLEMENT PROVIDE? If the settlement is approved, or after any potential appeals of that approval are resolved, Labcorp has agreed to the following terms: * Not using or enabling certain tracking technologies (as defined by the settlement agreement, but examples include the Meta Pixel and Google Analytics) on its website, labcorp.com or any of its subpages, for two years; * Conducting an annual review and preparing a compliance report demonstrating that it is not using technologies prohibited by the settlement; * Creating or maintaining a written policy regarding the appropriate use of externally developed tracking technologies on its website; and * Designating a senior employee responsible for overseeing compliance with the above terms. YOUR OPTIONS. The settlement provides only injunctive relief (e.g., business practice terms). Under the settlement terms, Settlement Class Members (except for Settlement Class Representatives) will not release any claims for damages or other monetary relief. If the settlement is approved, you will give up the right to sue Labcorp and other affiliated entities for injunctive relief claims arising from or related to the allegations in this lawsuit. Because the plaintiffs are seeking only injunctive relief and because Labcorp is only agreeing to injunctive relief, Settlement Class Members cannot opt out of the settlement. This means that all members of the Settlement Class will be bound by the settlement, if the Court approves it. If you are a Settlement Class Member, you may object to or comment upon the proposed settlement, explaining why you believe the settlement should not be approved. All objections must be postmarked by November 23, 2026. For more information on how to object, visit www.LaboratoryCorporationWebsiteSettlement.com or call 1-877-378-7520. At the Final Approval Hearing, the Court will consider whether the settlement is fair, reasonable, and adequate, and whether to award attorneys' fees, expenses, and service awards, and in what amounts. If there are objections, the Court will consider them. After the hearing, the Court will decide whether to approve the Settlement. It is not necessary for you to attend this hearing, but you may attend at your own expense. If you have any questions or want more information about the settlement, please visit www.LaboratoryCorporationWebsiteSettlement.com or contact the Settlement Administrator at 1-877-378-7520. SOURCE U.S. District Court for the Middle District of North Carolina